LIDDS Email Format
Biotechnology ResearchUppsala, Sweden2-10 Employees
LIDDS is a Swedish biotechnology research company based in Uppsala, with a small staff of 2–10 employees. It develops local drug delivery formulations using its proprietary NanoZolid technology, enabling controlled drug release for up to six months at the site of administration. The company has engaged in oncology related work, including a 2021 agreement with Johnson & Johnson Enterprise Innovation to develop an oncology product using NanoZolid, and in 2024 it acquired Noviga Research AB. Leadership at LIDDS has evolved, with Jenni Björnulfson named CEO in November 2023 and Matthew Lindon serving as acting CEO starting in August 2023, along with earlier executive appointments in 2021–2022. The company maintains a website at liddspharma.com and reports revenue in the range of zero to one million dollars, with funding of about four point four million dollars.